- Previous close
16.06 - Open
16.06 - Bid 17.73 x 100
- Ask 18.20 x 400
- Day's range
15.91 - 19.33 - 52-week range
10.87 - 24.74 - Volume
2,500,775 - Avg. Volume
1,021,398 - Market cap (intra-day)
1.924B - Beta (5Y monthly) 0.70
- PE ratio (TTM)
-- - EPS (TTM)
-1.58 - Earnings date 30 Oct 2024
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
27.00
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
www.novocure.com1,453
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Medical Devices
Industry
Recent news: NVCR
View more
Performance overview: NVCR
Trailing total returns as of 15/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: NVCR
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: NVCR
View moreValuation measures
Market cap
1.92B
Enterprise value
1.65B
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
3.46
Price/book (mrq)
5.32
Enterprise value/revenue
3.00
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
-30.67%
Return on assets (ttm)
-9.30%
Return on equity (ttm)
-43.40%
Revenue (ttm)
549.96M
Net income avi to common (ttm)
-168.7M
Diluted EPS (ttm)
-1.58
Balance sheet and cash flow
Total cash (mrq)
951.19M
Total debt/equity (mrq)
186.65%
Levered free cash flow (ttm)
-24.58M